Cargando…

Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study

BACKGROUND AND AIMS: Treatment‐resistant depression (TRD), defined as inadequate treatment response after at least two adequate treatment trials, is common among patients initiating antidepressant treatment. Current or previous substance use disorders (SUD) are common among patients with depression...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenner, Philip, Brandt, Lena, Li, Gang, DiBernardo, Allitia, Bodén, Robert, Reutfors, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078870/
https://www.ncbi.nlm.nih.gov/pubmed/31656053
http://dx.doi.org/10.1111/add.14866
_version_ 1783507707747106816
author Brenner, Philip
Brandt, Lena
Li, Gang
DiBernardo, Allitia
Bodén, Robert
Reutfors, Johan
author_facet Brenner, Philip
Brandt, Lena
Li, Gang
DiBernardo, Allitia
Bodén, Robert
Reutfors, Johan
author_sort Brenner, Philip
collection PubMed
description BACKGROUND AND AIMS: Treatment‐resistant depression (TRD), defined as inadequate treatment response after at least two adequate treatment trials, is common among patients initiating antidepressant treatment. Current or previous substance use disorders (SUD) are common among patients with depression and often lead to worse treatment outcomes. However, in clinical studies, SUD have not been found to increase the risk for TRD. The aim of this study was to investigate the association between SUD and TRD. DESIGN: Nested case–control study. SETTING: Nation‐wide governmental health‐care registers in Sweden. CASES AND CONTROLS: Data on prescribed drugs and diagnoses from specialized health care were used to establish a prospectively followed cohort of antidepressant initiators with depression (n = 121 669) from 2006 to 2014. Of these, 15 631 patients (13%) were defined as TRD cases, with at least three treatment trials within a single depressive episode. Each case with TRD was matched on socio‐demographic data with five controls with depression. MEASUREMENTS: Crude and adjusted odds ratios (aOR) with 95% confidence intervals (CI) estimated the association between TRD and SUD diagnosis and/or treatment in five different time intervals until the time for fulfillment of TRD definition for the case. The analysis was adjusted for clinical and socio‐demographic covariates. FINDINGS: Having any SUD during, or ≤ 180 days before start of, antidepressant treatment was associated with almost double the risk for TRD [≤ 180 days before: adjusted OR (aOR) = 1.86, CI = 1.70–2.05]. Increased risks for TRD were found ≤ 180 days before treatment start for the subcategories of sedative use (aOR = 2.37; 1.88–2.99), opioids (aOR = 2.02; 1.48–2.75), alcohol (aOR = 1.77; CI = 1.59–1.98) and combined substance use (aOR = 2.31; 1.87–2.99). CONCLUSIONS: Recent or current substance use disorders is positively associated with treatment resistance among patients initiating treatment for depression.
format Online
Article
Text
id pubmed-7078870
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70788702020-03-19 Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study Brenner, Philip Brandt, Lena Li, Gang DiBernardo, Allitia Bodén, Robert Reutfors, Johan Addiction Research Reports BACKGROUND AND AIMS: Treatment‐resistant depression (TRD), defined as inadequate treatment response after at least two adequate treatment trials, is common among patients initiating antidepressant treatment. Current or previous substance use disorders (SUD) are common among patients with depression and often lead to worse treatment outcomes. However, in clinical studies, SUD have not been found to increase the risk for TRD. The aim of this study was to investigate the association between SUD and TRD. DESIGN: Nested case–control study. SETTING: Nation‐wide governmental health‐care registers in Sweden. CASES AND CONTROLS: Data on prescribed drugs and diagnoses from specialized health care were used to establish a prospectively followed cohort of antidepressant initiators with depression (n = 121 669) from 2006 to 2014. Of these, 15 631 patients (13%) were defined as TRD cases, with at least three treatment trials within a single depressive episode. Each case with TRD was matched on socio‐demographic data with five controls with depression. MEASUREMENTS: Crude and adjusted odds ratios (aOR) with 95% confidence intervals (CI) estimated the association between TRD and SUD diagnosis and/or treatment in five different time intervals until the time for fulfillment of TRD definition for the case. The analysis was adjusted for clinical and socio‐demographic covariates. FINDINGS: Having any SUD during, or ≤ 180 days before start of, antidepressant treatment was associated with almost double the risk for TRD [≤ 180 days before: adjusted OR (aOR) = 1.86, CI = 1.70–2.05]. Increased risks for TRD were found ≤ 180 days before treatment start for the subcategories of sedative use (aOR = 2.37; 1.88–2.99), opioids (aOR = 2.02; 1.48–2.75), alcohol (aOR = 1.77; CI = 1.59–1.98) and combined substance use (aOR = 2.31; 1.87–2.99). CONCLUSIONS: Recent or current substance use disorders is positively associated with treatment resistance among patients initiating treatment for depression. John Wiley and Sons Inc. 2019-12-16 2020-04 /pmc/articles/PMC7078870/ /pubmed/31656053 http://dx.doi.org/10.1111/add.14866 Text en © 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Reports
Brenner, Philip
Brandt, Lena
Li, Gang
DiBernardo, Allitia
Bodén, Robert
Reutfors, Johan
Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study
title Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study
title_full Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study
title_fullStr Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study
title_full_unstemmed Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study
title_short Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study
title_sort substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078870/
https://www.ncbi.nlm.nih.gov/pubmed/31656053
http://dx.doi.org/10.1111/add.14866
work_keys_str_mv AT brennerphilip substanceusedisordersandriskfortreatmentresistantdepressionapopulationbasednestedcasecontrolstudy
AT brandtlena substanceusedisordersandriskfortreatmentresistantdepressionapopulationbasednestedcasecontrolstudy
AT ligang substanceusedisordersandriskfortreatmentresistantdepressionapopulationbasednestedcasecontrolstudy
AT dibernardoallitia substanceusedisordersandriskfortreatmentresistantdepressionapopulationbasednestedcasecontrolstudy
AT bodenrobert substanceusedisordersandriskfortreatmentresistantdepressionapopulationbasednestedcasecontrolstudy
AT reutforsjohan substanceusedisordersandriskfortreatmentresistantdepressionapopulationbasednestedcasecontrolstudy